Rocca Fortunato R.
Known title: President and CEOCIK: 0001492734
Associated companies
Transaction History
| XGN | ▼ Sell | Tax Withholding | 4,322 | $31K | 3/1/2022 | View on chart |
| XGN | ▲ Buy | Grant | 75,000 | $0 | 2/4/2022 | View on chart |
| XGN | ▼ Sell | Tax Withholding | 4,322 | $31K | 3/1/2022 | View on chart |
| XGN | ▲ Buy | Grant | 75,000 | $0 | 2/4/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
TD Cowen Raises Exagen Price Target to $11
TD Cowen has maintained its positive stance on Exagen, raising its price target to $11. This update aligns with the broader analyst consensus, where the average target sits at $10.14. The move provides context for the stock's current position within its 52-week range of $2.59 to $12.23.
TD Cowen Raises Exagen Price Target to $11. TD Cowen has maintained its positive stance on Exagen, raising its price target to $11. This update aligns with the broader analyst consensus, where the average target sits at $10.14. The move provides context for the stock's current position within its 52-week range of $2.59 to $12.23.